Alliqua BioMedical, Inc. Announces Expansion of Medicare Reimbursement Coverage for MIST Therapy®
Alliqua BioMedical, Inc. to Acquire Soluble Systems, LLC
Alliqua BioMedical, Inc. Announces Preliminary Third Quarter of Fiscal Year 2016 Revenue; Earnings Conference Call Scheduled for November 4th
Alliqua BioMedical, Inc. Expands Regenerative Medicine Portfolio with the Commercial Introduction of Interfyl Connective Tissue Matrix
Alliqua BioMedical, Inc. Reports Second Quarter and Six Months Fiscal Year 2016 Financial Results
Alliqua BioMedical, Inc. and BSN medical, Inc. Announce Definitive Agreement on Distribution Rights for Sorbion Dressing Products in the U.S., Canada and Latin America; Alliqua Updates Fiscal Year 2016 Outlook
Alliqua BioMedical, Inc. Announces Preliminary Second Quarter of Fiscal Year 2016 Revenue; Earnings Conference Call Scheduled for August 9th
Alliqua BioMedical, Inc. to Attend Craig-Hallum Institutional Investor Conference
Alliqua BioMedical, Inc. Reports First Quarter Financial Results
Alliqua BioMedical, Inc. to Announce First Quarter of Fiscal Year 2016 Results on May 10th
Alliqua BioMedical Presents at the Spring 2016 SAWC Meeting
Alliqua BioMedical to Present at the 15th Annual Needham Healthcare Conference
Alliqua BioMedical, Inc. Announces Participation in the Blue Cross Blue Shield Association’s Evidence Street Pilot Program
Alliqua BioMedical, Inc. Announces Expansion of Medicare Reimbursement Coverage for Biovance®
Alliqua BioMedical, Inc. Reports Fourth Quarter and Fiscal Year 2015 Financial Results
Alliqua BioMedical Announces Changes to Its Board of Directors
Alliqua BioMedical to Present at Upcoming Investor Conferences
Alliqua BioMedical, Inc. to Announce Fourth Quarter and Fiscal Year 2015 Results on February 23rd
Alliqua’s UltraMIST® System Honored With GOOD DESIGN Award
Alliqua Biomedical Announces Partnership With Human Longevity Inc., Under Existing Licensing Agreement
Alliqua BioMedical Announces Agreement With HealthTrust
Alliqua BioMedical, Inc. to Attend November Healthcare Conferences
Alliqua BioMedical, Inc. Reports Third Quarter Financial Results
Alliqua BioMedical, Inc. to Announce Third Quarter of Fiscal Year 2015 Results on November 5th
Poster on Use of Biovance(R) for Treatment of Venous Ulcers to be Featured at the Fall 2015 Symposium on Advanced Wound Care
Alliqua BioMedical, Inc. to Present at Upcoming Investor Conferences
Alliqua BioMedical, Inc. to Attend 2015 Midwest IDEAS Investor Conference
Alliqua BioMedical, Inc. Reports Second Quarter Financial Results
Alliqua BioMedical, Inc. to Announce Second Quarter of Fiscal Year 2015 Results on August 6th
Alliqua BioMedical, Inc. to Ring the Nasdaq Stock Market Opening Bell on July 6th
Alliqua BioMedical, Inc. Announces the Publication of Results From a Biovance(R) Use Registry Study in WOUNDS
Alliqua BioMedical, Inc. Appoints Nino Pionati as Chief Strategy and Marketing Officer
Alliqua BioMedical, Inc. Announces Closing of Celleration, Inc. Acquisition
Alliqua BioMedical, Inc. Reports First Quarter Financial Results
Alliqua BioMedical, Inc. to Attend Craig-Hallum Institutional Investor Conference
Alliqua Biomedical Announces Expansion to Its Exclusive Licensing Agreement with Celgene Cellular Therapeutics
Alliqua BioMedical Presents at the Spring 2015 Symposium on Advanced Wound Care
Alliqua BioMedical, Inc. to Announce First Quarter of Fiscal Year 2015 Results on May 14th
Alliqua BioMedical, Inc. Announces Closing of $34.5 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares
Alliqua BioMedical, Inc. Announces Pricing of Public Offering of Common Stock
Alliqua BioMedical, Inc. Announces Proposed Public Offering of Common Stock
Alliqua BioMedical, Inc. Announces Preliminary First Quarter 2015 Revenue Results & Updates Fiscal Year 2015 Revenue Guidance
Alliqua BioMedical, Inc. Receives Coverage From Medicare Administrative Contractor (MAC) for Biovance(R)
Alliqua BioMedical, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results
Alliqua BioMedical, Inc. to Present at Upcoming Investor Conferences
Alliqua BioMedical, Inc. to Announce Fourth Quarter and Fiscal Year 2014 Results on February 24th
Alliqua BioMedical, Inc. to Acquire Celleration, Inc.
Alliqua BioMedical Announces Group Purchasing Agreement With Premier, Inc.
Alliqua BioMedical, Inc.'s Biovance(R) Assigned Level II HCPCS Q Code for Product Reimbursement
Alliqua BioMedical, Inc. Reports Third Quarter 2014 Financial Results
Alliqua BioMedical, Inc. to Announce Third Quarter Financial Results on October 30th
Abstract on Alliqua's Biovance(R) Product to Receive Award at the Fall 2014 Symposium on Advanced Wound Care
Alliqua Biomedical Announces Expansion to Its Exclusive Licensing Agreement With Celgene Cellular Therapeutics
Alliqua BioMedical to Present at Upcoming Investor Conferences
Alliqua Biomedical, Inc. Reports Second Quarter 2014 Financial Results
Alliqua BioMedical Announces Changes to Its Board of Directors
Alliqua BioMedical's CEO Issues Midyear Corporate Update for Shareholders
Alliqua BioMedical Added to the Russell Microcap(R) Index
Alliqua Reincorporates in State of Delaware, De-Staggers Board and Changes Name to Alliqua BioMedical
Alliqua Reports First Quarter 2014 Financial Results
Alliqua Acquires Choice Therapeutics
Alliqua to Launch Biovance(R) Human Amniotic Membrane Allograft Product Licensed From Celgene
Alliqua Biomedical Announces New Data on sorbion(R) Wound Care Dressings to be Presented at the Spring 2014 SAWC Meeting
UPDATE -- Alliqua Raises $20.3 Million in Private Placement of Equity and Exercise of Warrants
Alliqua Raises $20.3 Million in Private Placement of Equity and Exercise of Warrants
Alliqua Appoints 20 Direct Sales Representatives to Strengthen Brand Awareness and Drive Greater Market Penetration in the U.S.
Alliqua Reports Fourth Quarter and Full Year 2013 Financial Results
Alliqua to Present at 26th Annual ROTH Conference on March 10
Alliqua, Inc. Profiled by TheStreet.com and Philadelphia Business Journal
Alliqua Appoints Janice M. Smiell, M.D. as its First Chief Medical Officer
Alliqua’s CEO Issues Letter to Shareholders
Alliqua to List on the NASDAQ Capital Market on January 28, 2014
Alliqua Appoints Perry A. Karsen to Board of Directors
Alliqua Announces Transaction with Celgene
Alliqua Announces Reverse Split of Common Stock
Alliqua Receives $1M from Crossover Healthcare Fund, LLC to Pursue Key Wound Care Initiatives
Alliqua Signs Distribution Agreement for SilverSeal® and Hydress® Wound Dressings
Preclinical Results Show Alliqua's Investigational Lidocaine Transdermal Patch Compares Favorably to Lidoderm Patch
Alliqua Provides Update on Media Coverage of its Advanced Wound Care Portfolio and Corporate Developments
Alliqua's SILVERSEAL Wound Outcome Data Presented at SAWC Fall Meeting
Alliqua Becomes Exclusive Distributor of sorbion-Branded Wound Products in the Americas Through Agreement with Carolon
Alliqua Signs Long-Term Distribution Agreement with sorbion for Hydroactive Wound Product Line with Hydration Response Technology
Alliqua Appoints Brian M. Posner as Chief Financial Officer
Alliqua Signs Distribution Agreement with Team Distributing International and World Health Industries for SilverSeal® and Hydress® Wound Dressings
Alliqua's CEO Issues Midyear Corporate Update for Shareholders
Alliqua Initiates Proof-of-Principle Study of Transdermal Lidocaine Hydrogel Patch for Pain Relief
Alliqua's SilverSeal Dressing Shown to Improve Surgical Wound Outcomes in Clinical Study
Alliqua Raises $3 Million in 2nd Quarter of 2013, Led by Members of Management and its Board of Directors
Alliqua to Present Results Demonstrating Antimicrobial Properties of SilverSeal® at SAWC SPRING 2013
Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications
Letter from Alliqua CEO, Dave Johnston, to Shareholders
Alliqua Demonstrates Wound Healing Benefit of SilverSeal® Dressing on Foot and Ankle Post-Surgical Wounds
Alliqua Strengthens and Realigns Executive Team
Alliqua to Present at Biotech Showcase 2013 on January 7, 2013
Alliqua Names David Johnson Executive Chairman of Aquamed Technologies and Member of Alliqua Board of Directors
Alliqua, Inc. Announces the Appointment of Jerome Zeldis as Chairman of its Board of Directors
Alliqua to Explore Business Development Efforts for Hydrogel Transdermal Delivery Platform in the Cosmeceutical Industry
Alliqua Appoints Dr. Joseph Laudano as Vice President of Medical Affairs to Support the Market Expansion of Alliqua's SilverSeal Products and Future Clinical Development
Alliqua Launches New Sales Initiative for SilverSeal(R) Hydrogels at Desert Foot 2012 Conference in Arizona on November 14-16
Alliqua Appoints James Sapirstein as CEO as Company Focuses on Strategic Growth Plan
Dr. Harold Schoenhaus Joins the Scientific Advisory Board of Alliqua
Alliqua Names Stephen A. Brigido, D.P.M. Chairman of Scientific Advisory Board
Dr. Charles J. Wolff to Serve on Alliqua Scientific Advisory Board
Alliqua Names Dr. Michael Moore to Its Scientific Advisory Board
Alliqua Names Jerome Zeldis, MD, PhD, to Its Board of Directors
Alliqua Announces Changes to Its Board of Directors
Frost Gamma Investments Trust Increases Stake in Alliqua, Inc.
Alliqua, Inc. Receives Healthcare Common Procedural Coding System ("HCPCS") Code for Its Silver Based Hydrogel Dressings
Alliqua, Inc. Provides Corporate Update, Plans for 2012
Alliqua Retains INC Research, LLC as Strategic Consultant
CORRECTING AND REPLACING: Alliqua, Inc. Acquires Exclusive License to Antimicrobial Wound Care Products from Noble Biomaterials, Inc.
Alliqua, Inc. Acquires Exclusive License to Antimicrobial Wound Care Products From Noble Biomaterials, Inc.
Alliqua, Inc. Expands Patent Portfolio for Transdermal Drug Delivery Platform
Alliqua, Inc. Announces Preparation of IND for PHN Patch
Alliqua, Inc. Files Provisional Patent in the U.S. for Transdermal Delivery System
Alliqua Successfully Completes Next Milestone in Transdermal Pain Patch Development
Alliqua to Announce Results of Initial Transdermal Pain Patch In Vitro Study; Results to be Released Monday
Frost Gamma Investments Trust Makes Strategic Investment in Alliqua, Inc.
Alliqua Announces the Successful Completion of Its Initial Study for the Transdermal Pain Patch
Alliqua Appoints Five New Directors to Its Board
Alliqua Announces Ticker Symbol Change to "ALQA" Effective January 5th
Alliqua Retains Industry Veteran Dr. Ronald S. Harland as Strategic Consultant
HepaLife Technologies Announces Name Change to "Alliqua, Inc."
HepaLife Technologies Announces 510(k) Submission to the FDA for Its Silver Based Antimicrobial Wound Dressing
HepaLife Technologies to Enter Pain Management Market with Its Transdermal Patch
HepaLife Technologies Launches Alliqua BioMedical to Capitalize on New Market Opportunities
HepaLife(TM) Expands Portfolio of Liver Products
HepaLife(TM) Announces Successful Acquisition of AquaMed Technologies, Inc.
Independent Report Projects HepaLife as a Leader in $1.5 Billion Liver Assist Market.
HepaLife Expands Advisory Board to Advance Plans for Bioartificial Liver Clinical Trial
HepaLife(TM) Plans for Phase III Clinical Trial for HepaMate(TM) Bioartificial Liver System
HepaLife(TM) Patented 'PICM-19' Liver Stem Cell Line Launched Onboard Space Shuttle "Endeavour"
HepaLife(TM) Acquires Liver Support Technology, Tested in America's Largest-Ever Human Clinical Trial for Bioartificial Liver Assist Devices
HepaLife(TM) Announces Expansion of Exclusive License Agreement with U.S. Government Agency for Liver Cell Line
HepaLife(TM) Develops New Liver Stem Cell Lines for Bioartificial Liver Device; Data Presented at Scientific Conferences
HepaLife(TM) Completes $4.5 Million Private Placement
HepaLife's Bioartificial Liver Exceeds Expectations in New Tests Conducted over Prolonged Periods of Time
New Artificial Liver Tests: HepaLife's 'PICM-19' Demonstrate Advantages Over Today's Best-Available Liver Cells
HepaLife(TM) to Present Bioartificial Liver Device Data at International Stem Cell Conference
HepaLife's Bioartificial Liver Successful in Important Studies Modeling Human Liver Failure Environment
HepaLife(TM) to Present New Bioartificial Liver Device Data at Major National Scientific Conference
Accomplished Executive with Regulatory Affairs/Quality Systems & Bioartificial Liver Device Expertise Joins HepaLife(TM)
HepaLife's Bioartificial Liver Dramatically Reduces Toxic Marker for Acute Liver Failure
HepaLife Announces Appointment of Dr. Christopher W. Kemp, Vice President of Research & Development
HepaLife(TM) Surpasses Significant Milestones in Development of Artificial Liver Device
HepaLife(TM) Enters Into New Cooperative Research and Development Agreement with U.S. Government Agency
HepaLife(TM) Announces Exclusive License Agreement with U.S. Government Agency for Liver Cell Lines
HepaLife(TM) Releases Positive New Research Results for First-of-Its-Kind Bioartificial Liver
Internationally Renowned Artificial Organs Expert Joins HepaLife(TM)
HepaLife(TM) Bioartificial Liver: Analysts Forecast Artificial Liver Market to Surpass $2.7 Billion by 2010
HepaLife Expands Scientific Team and Continues Development of First-of-its-Kind Artificial Liver Device
HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
HepaLife Completes Private Placement for $2.5 Million
HepaLife Expands Management Team on Heels of Favorable Outcomes of First-of-Its-Kind Bioartificial Liver Device
HepaLife Achieves Major Milestone in Development of Artificial Liver Device
HepaLife's Cells for Artificial Liver Device Significantly Outperform Most-Widely Used Human Liver Cell Line
HepaLife's Patented ''PBS-1'' Cells for Avian Flu Vaccines Outperform Current Cell System by 500%
HepaLife Announces Appointment of Senior Medical Device and Healthcare Executive to the Board of Directors
Positive Research Findings Accelerate HepaLife's Development of Artificial Liver Device
Internationally Renowned Expert in Artificial Liver Device Development Joins HepaLife
HepaLife Surpasses Major Milestone in Cell-Based Vaccine Development for Avian Influenza
Pioneering Vaccine and Cell Culture Expert Joins HepaLife to Expedite Development of Avian Flu Vaccine
